NEW YORK (GenomeWeb News) – DioGenix announced today a collaboration with Fast Forward to develop a molecular diagnostic test for multiple sclerosis.

As part of the deal, Fast Forward, a subsidiary of the National Multiple Sclerosis Society, will provide DioGenix $500,000 to expand its ongoing clinical trial for MSPrecise, a diagnostic test based on next-generation sequencing to measure genetic mutations in the adaptive immune system by analyzing B cells isolated from cerebral spinal fluid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.